RBCC Appoints New CEO to Achieve Regenerative Medicine Goals

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Growing biotechnology innovator Rainbow Coral Corp. (OTCBB: RBCC) announced today that the company has appointed Kimberly Palmer as new president and CEO.

A registered nurse with extensive healthcare experience, Palmer will be tasked with implementing RBCC's developing business strategy in the field of regenerative medicine. For the past eight years, she has served as a business consultant to private surgeons, providing administrative and clinical support for a variety of medical practices. She also brings extensive experience with surgical pre- and post-operative patient care to RBCC.

At RBCC, Palmer will spearhead the marketing and development of new breakthroughs in regenerative and precision medicine. In recent years, major discoveries in the usage of adult stem cells and biologics have led to promising advances in the treatment of illnesses from chronic back pain to leukemia and even AIDS.

With new, uniquely patentable regenerative therapies being developed all over the U.S., RBCC is reaching out to emerging industry leaders regarding development partnerships expected to significantly boost the company's bottom line.

"We are entering an exciting new chapter in the history of medicine, and RBCC is right on the cutting-edge of this new field of regenerative therapy," Palmer said. "I look forward to leading this growing company into a very bright future for our partners and investors."

By acquiring or partnering with up-and-coming regenerative therapy companies, RBCC plans to be well-positioned to capitalize on the big growth in store for the industry. The company invests in technology developed to compete in the biotechnology industry alongside Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).

For more information on RBCC's other biotech initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.


Rainbow Coral Corp.

Patrick Brown, 850-269-7230

President and CEO

[email protected]